Form 4: Vertex Pharma Exec Gains Shares from Performance Awards

Vertex Pharmaceuticals' EVP, Chief Operating Officer, and Chief Financial Officer, Charles F. Wagner Jr., acquired 13,600 shares of common stock through the vesting of performance stock unit awards.

Summary

• Charles F. Wagner Jr., Executive Vice President, Chief Operating Officer, and Chief Financial Officer of Vertex Pharmaceuticals Inc., acquired 9,440 shares of common stock.
• These 9,440 shares were earned performance shares from a performance stock unit award granted on February 1, 2023, with performance-vesting requirements certified on January 22, 2026, and scheduled to vest on February 13, 2026.
• An additional 4,160 shares of common stock were acquired.
• These 4,160 shares were earned performance shares from a performance stock unit award granted on February 12, 2025, with performance-vesting requirements certified on January 22, 2026, and scheduled to vest in installments beginning on February 24, 2026.
• Following these transactions, Charles F. Wagner Jr. beneficially owns a total of 51,325 shares of common stock.

Sentiment

Score: 7

Explanation: The vesting of performance stock units indicates that the company's performance goals, tied to these awards, were met, which is generally a positive sign for the company and its executive.

Positives

• The vesting of performance stock units indicates that the company's management development and compensation committee certified the attainment of performance goals, reflecting positive operational or financial performance by the company.

Future Outlook

The shares acquired from the performance stock unit awards are scheduled to vest on February 13, 2026, and in installments beginning February 24, 2026, indicating future beneficial ownership changes.

Management Comments

• The issuer's management development and compensation committee certified the attainment of performance goals for the awarded stock units.

Industry Context

This filing represents a routine executive compensation event, common in the biotechnology and pharmaceutical industries, where performance-based equity awards are a standard component of executive remuneration packages.

Stakeholder Impact

• Shareholders: The vesting of performance-based awards suggests that the company has met certain performance targets, which could be viewed positively.
• Employees (Executive): Charles F. Wagner Jr. directly benefits from the vesting of these awards, increasing his equity stake in the company.

Next Steps

• The 9,440 earned performance shares will vest on February 13, 2026.
• The 4,160 earned performance shares will vest in installments beginning on February 24, 2026.

Key Dates

Keywords

Vertex Pharmaceuticals, VRTX, Form 4, Insider Transaction, Stock Award, Performance Shares, Executive Compensation, Charles F. Wagner Jr.